Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Part of paid clinical trials in Anaheim, California.

Sponsor
Amgen
Study ID
NCT07226778
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Maridebart Cafraglutide — DRUG
    Maridebart cafraglutide will be administered SC.

Study Details

The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

Key Dates

First listed
Nov 10, 2025
Start date
Oct 10, 2025
Status verified
Jun 2026
Primary completion
May 28, 2026
Completion
May 28, 2026

Study Design

Enrollment
348 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Maridebart Cafraglutide SC Presentation 1
    Participants will receive a single dose of maridebart cafraglutide administered using SC presentation 1.
  • Active Comparator: Maridebart Cafraglutide SC Presentation 2
    Participants will receive a single dose of maridebart cafraglutide administered using SC presentation 2.

Primary Outcome Measure

Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart Cafraglutide [ Time Frame: Up to Day 120 ]

Locations (4)

FacilityCityStateZIPSite coordinators
Anaheim Clinical TrialsAnaheimCalifornia92801-2658-
Fortrea Clinical Research Unit - Daytona BeachDaytona BeachFlorida32117-5116-
Fortrea Clinical Research Unit - DallasDallasTexas75247-4989-
Fortrea Clinical Research Unit Inc. - MadisonMadisonWisconsin53704-2526-

Find similar trials in Anaheim, CA

Related Studies